FDA Calls Out “Egregious” Novartis Petition; Firm Asks Agency To Be Nicer
Executive Summary
After the agency reproaches Novartis for what it called a tardy petition seeking to block generic versions of Reclast, the firm offers more information, not in an effort to get FDA to change its mind, but just to change its tone.